202 related articles for article (PubMed ID: 20856130)
1. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
3. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Henrich TJ; Lewine NR; Lee SH; Rao SS; Berro R; Gulick RM; Moore JP; Tsibris AM; Kuritzkes DR
Antimicrob Agents Chemother; 2012 Apr; 56(4):1931-5. PubMed ID: 22252820
[TBL] [Abstract][Full Text] [Related]
4. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
[TBL] [Abstract][Full Text] [Related]
5. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
Berro R; Klasse PJ; Jakobsen MR; Gorry PR; Moore JP; Sanders RW
Virology; 2012 Jun; 427(2):158-65. PubMed ID: 22424737
[TBL] [Abstract][Full Text] [Related]
6. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
[TBL] [Abstract][Full Text] [Related]
7. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
[TBL] [Abstract][Full Text] [Related]
8. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
Armand-Ugón M; Moncunill G; Gonzalez E; Mena M; Ballana E; Clotet B; Esté JA
J Antimicrob Chemother; 2010 Mar; 65(3):417-24. PubMed ID: 20067983
[TBL] [Abstract][Full Text] [Related]
9. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
[TBL] [Abstract][Full Text] [Related]
10. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Tsibris AM; Hu Z; Paredes R; Leopold KE; Putcharoen O; Schure AL; Mazur N; Coakley E; Su Z; Gulick RM; Kuritzkes DR
J Virol; 2012 Jun; 86(12):6416-26. PubMed ID: 22491471
[TBL] [Abstract][Full Text] [Related]
11. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
12. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
Tsibris AM; Sagar M; Gulick RM; Su Z; Hughes M; Greaves W; Subramanian M; Flexner C; Giguel F; Leopold KE; Coakley E; Kuritzkes DR
J Virol; 2008 Aug; 82(16):8210-4. PubMed ID: 18495779
[TBL] [Abstract][Full Text] [Related]
13. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
[TBL] [Abstract][Full Text] [Related]
14. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
15. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
McNicholas PM; Mann PA; Wojcik L; Qiu P; Lee E; McCarthy M; Shen J; Black TA; Strizki JM
J Acquir Immune Defic Syndr; 2011 Mar; 56(3):222-9. PubMed ID: 21209592
[TBL] [Abstract][Full Text] [Related]
16. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
[TBL] [Abstract][Full Text] [Related]
17. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
[TBL] [Abstract][Full Text] [Related]
19. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.
Ratcliff AN; Shi W; Arts EJ
J Virol; 2013 Jan; 87(2):923-34. PubMed ID: 23135713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
